XOMA (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average of $19.48

XOMA Co. (NASDAQ:XOMAGet Rating)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $19.48 and traded as high as $22.50. XOMA shares last traded at $21.70, with a volume of 21,243 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of XOMA in a research note on Wednesday, October 12th. They issued a “hold” rating for the company.

XOMA Stock Performance

The firm has a market cap of $248.49 million, a PE ratio of 63.82 and a beta of 0.90. The company’s 50-day simple moving average is $20.06 and its two-hundred day simple moving average is $19.48.

XOMA (NASDAQ:XOMAGet Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.28). The firm had revenue of $0.45 million for the quarter, compared to analysts’ expectations of $9.10 million. XOMA had a net margin of 22.25% and a return on equity of 6.59%. On average, analysts expect that XOMA Co. will post -1.8 EPS for the current year.

Insider Buying and Selling at XOMA

In other news, Director Bvf Partners L. P/Il purchased 19,000 shares of the company’s stock in a transaction on Thursday, January 5th. The stock was acquired at an average price of $18.39 per share, with a total value of $349,410.00. Following the transaction, the director now directly owns 1,788,168 shares of the company’s stock, valued at approximately $32,884,409.52. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. BVF Inc. IL raised its holdings in XOMA by 2.3% in the 3rd quarter. BVF Inc. IL now owns 3,611,494 shares of the biotechnology company’s stock worth $64,682,000 after purchasing an additional 80,951 shares in the last quarter. FMR LLC raised its holdings in XOMA by 20.4% in the 2nd quarter. FMR LLC now owns 1,130,184 shares of the biotechnology company’s stock worth $25,180,000 after purchasing an additional 191,703 shares in the last quarter. Rubric Capital Management LP raised its holdings in XOMA by 34.4% in the 3rd quarter. Rubric Capital Management LP now owns 200,785 shares of the biotechnology company’s stock worth $3,596,000 after purchasing an additional 51,339 shares in the last quarter. State Street Corp raised its holdings in XOMA by 1.1% in the 1st quarter. State Street Corp now owns 131,340 shares of the biotechnology company’s stock worth $3,675,000 after purchasing an additional 1,464 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in XOMA by 254.6% in the 2nd quarter. Millennium Management LLC now owns 89,055 shares of the biotechnology company’s stock worth $1,984,000 after purchasing an additional 63,944 shares in the last quarter. 54.89% of the stock is currently owned by institutional investors.

About XOMA

(Get Rating)

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Recommended Stories

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.